Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies delivered into the suprachoroidal space of the eye. Its commercial product, XIPERE, is licensed to partners in the U.S., Canada and parts of Asia-Pacific, while the company’s internal development efforts are centered on CLS-AX and other eye-disease candidates using its SCS Microinjector platform.
Fiscal year 2024 · change from previous year
Development 2019–2024
Business
Share of revenueXIPERE is the company’s approved therapy delivered into the suprachoroidal space for eye disease.
The SCS Microinjector platform enables targeted suprachoroidal administration of ophthalmic therapies.
Upfront, milestone and royalty-based payments from partners using the platform or product rights.
CLS-AX and other proprietary ophthalmic candidates under preclinical and clinical development.
Products
Reported · share of revenue- License99.4 %
- Other Agreement0.6 %
Source: 10-K FY2023, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Clearside sells primarily to pharmaceutical and ophthalmology partners rather than to end patients directly. Its commercial model depends on licensing XIPERE and the SCS Microinjector to companies that can market and distribute in specific territories, while also pursuing collaborations for new eye-disease candidates. The company’s direct customer base is therefore a mix of licensees, collaborators and, to a limited extent, approved-product purchasers of Microinjector kits.
Partners such as Bausch + Lomb and Arctic Vision that commercialize XIPERE in licensed territories.
Pharma and biotech companies that pay for access to the SCS Microinjector and related know-how.
Licensees that buy SCS Microinjector kits for use with approved ophthalmic products.
Potential partners for CLS-AX and other candidates if Clearside chooses to out-license development or commercialization.
Strategy
Clearside’s near-term strategy is to preserve cash while advancing CLS-AX and other proprietary ophthalmic candidates through development and regulatory milestones. At the same time, it is trying to expand the platform through additional licensing and collaboration agreements that can generate upfront, milestone and royalty revenue without requiring a large commercial infrastructure. The company is also evaluating strategic alternatives and financing options because its current cash runway is limited.
The company needs a successful late-stage asset to create future product revenue and reduce dependence on licensing income.
Additional collaborations can generate non-dilutive cash and validate the SCS Microinjector in more indications.
The company has a limited cash runway and needs capital to continue development and avoid forced restructuring.
Geography
Clearside is headquartered in the United States and its commercial footprint is shaped by partner territories rather than a broad direct-sales network. XIPERE commercialization rights are licensed in the United States and Canada to Bausch + Lomb and in Asia-Pacific, excluding Japan, to Arctic Vision, with Health Canada approval received in July 2025. As a result, geographic exposure is concentrated in North America and selected Asia-Pacific markets, while development, regulatory and financing activities remain U.S.-centered.
Risks
Clearside faces substantial going-concern and financing risk because it has recurring losses, negative operating cash flow and limited cash runway. Its business also depends on partner execution, regulatory outcomes and the ability to convert its platform into approved products and royalty streams, while any failure to complete a strategic alternative could lead to wind-down or liquidation.
- Going-concern and financing shortfallImpact: CriticalLikelihood: High
The company expects to need additional capital to fund operations and complete CLS-AX development.
Exposure - Strategic alternative / liquidation riskImpact: CriticalLikelihood: High
Management disclosed that failure to complete a strategic alternative could lead to bankruptcy, wind-down or dissolution.
Exposure: Residual value for common shareholders
- Clinical and regulatory failure for CLS-AXImpact: High
Pipeline value depends on successful development and approval of the lead candidate.
Exposure: R&D spend and future product revenue
- Partner and licensing concentrationImpact: High
Revenue has historically come mainly from license agreements and collaboration payments.
Exposure: XIPERE territories and future platform deals
- Nasdaq delisting riskImpact: MediumLikelihood: High
Non-compliance with listing requirements could reduce liquidity and investor access.
Exposure: Trading price and marketability of shares
Accounting
Judgemental itemsRevenue is tied to upfront payments, milestones and obligations under partner agreements, so timing can shift between periods.
Impact: Can create lumpy quarterly revenue and non-cash revenue recognition
The liability related to sales of future royalties uses imputed interest and amortization assumptions.
Impact: Affects interest expense and carrying value of the financing liability
Warrants issued in financing transactions are remeasured through earnings.
Impact: Can cause non-operating income statement volatility
Management estimates costs for CROs, manufacturing and clinical studies based on incomplete information.
Impact: Can move research expense and operating loss timing
Similar listed companies
Publicly listed companies with a comparable business focus.
Axsome Therapeutics, Inc.
AXSM · Pharmaceutical Preparations
Axsome Therapeutics is a U.S.-based biopharmaceutical company focused on central nervous system (CNS) disorders, with a commercial portfolio built around AUVELITY, SUNOSI, and SYMBRAVO.
Xeris Biopharma Holdings, Inc.
XERS · Pharmaceutical Preparations
ClearPoint Neuro, Inc.
CLPT · Surgical & Medical Instruments & Apparatus
Arrowhead Pharmaceuticals, Inc
ARWR · Pharmaceutical Preparations
Arrowhead Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing RNA interference medicines that silence disease-causing genes.
OKYO Pharma Ltd
OKYO · Biological Products, (No Diagnostic Substances)
OKYO Pharma Ltd is a U.S.-listed clinical-stage biopharmaceutical company focused on developing investigational therapies for neuropathic corneal pain and other anterior segment eye diseases.
Milestone Pharmaceuticals Inc.
MIST · Pharmaceutical Preparations
Last updated: 24/09/2026